ACTU – actuate therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% [Yahoo! Finance]
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Actuate Therapeutics (NASDAQ:ACTU) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation [Yahoo! Finance]
Form 144 ACTUATE THERAPEUTICS, Filed by: Kairos Venture Partners II, L.P.
Form 8-K ACTUATE THERAPEUTICS, For: Nov 28
Form 424B5 ACTUATE THERAPEUTICS,
Form 8-K ACTUATE THERAPEUTICS, For: Nov 21
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.